Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in Maryland?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes. A Maryland resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Maryland-licensed prescriber, including through telehealth, and Maryland's telehealth statute (Health Occupations Article, section 1-1001 and following) expressly lets a practitioner perform the clinical evaluation required before treatment through either a synchronous or an asynchronous interaction. A static online questionnaire alone is not enough under the Board of Physicians rule (COMAR 10.32.05.06). A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy holding a Maryland pharmacy permit; out-of-state pharmacies need a Maryland nonresident pharmacy permit, which requires a recent home-state inspection report and a Maryland agent for service of process.

Regulatory: Telehealth allowedRegulatory: Async allowedRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 28, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous allowed; a questionnaire alone is not enough
Compounded GLP-1
Limited

Can a Maryland resident get peptides by telehealth?

Health Occupations Article sections 1-1001 through 1-1006, added in 2020 (Chapter 15, House Bill 448), govern telehealth by licensed health care practitioners. Telehealth includes both synchronous and asynchronous interactions, and an asynchronous telehealth interaction is an exchange of information that does not occur in real time, including the secure transmission of medical information, clinical data, images, lab results, and self-reported medical history. Section 1-1002 lets a practitioner establish a practitioner-patient relationship through either a synchronous or an asynchronous telehealth interaction after verifying the patient's identity, disclosing the practitioner's name, contact information, and license type, and obtaining consent. Section 1-1003 requires a clinical evaluation appropriate for the patient and condition before treating or prescribing through telehealth and states that the evaluation may be synchronous or asynchronous; telehealth care is held to the in-person standard. The in-person assessment limit in section 1-1003 applies only to Schedule II opiates prescribed for pain. The Maryland Board of Physicians rules (COMAR 10.32.05, amended effective September 15, 2025) repeat these standards, require a Maryland license, and bar treating or prescribing based solely on a static online questionnaire. Care delivered solely by audio-only calls, e-mail, or fax is not telehealth. The peptides in this database are not controlled substances. This record classifies asynchronous prescribing as allowed because the statute expressly permits an asynchronous interaction both to establish the relationship and to perform the required clinical evaluation; a static questionnaire alone is not enough. [2] [3] [4] [5] [6]

How does the Maryland pharmacy board treat compounding?

Compounding regulator for Maryland
BoardMaryland Board of Pharmacy (Maryland Department of Health)
Eligible substancesFollows the federal 503A framework

The Maryland Board of Pharmacy regulates pharmacists and pharmacies under Health Occupations Article, Title 12, and COMAR Title 10, Subtitle 34, including COMAR 10.34.19 on sterile pharmaceutical compounding. Maryland has no state bulks list; eligibility of a peptide for compounding follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Under Health Occupations section 12-403, a nonresident pharmacy that dispenses to Maryland patients must hold a Maryland pharmacy permit, submit the most recent inspection report from its home-state regulator, and designate a Maryland agent for service of process. Maryland no longer issues a separate sterile compounding permit: Chapter 5 of the Acts of 2015 (Senate Bill 69) repealed the sterile compounding permit requirement. Instead, section 12-403 requires a nonresident pharmacy that will dispense compounded sterile preparations to Maryland patients to submit a report of an inspection, conducted within 90 days before its application by a Board designee or another Board-approved entity, that shows compliance with USP chapter 797, and to keep complying with USP chapter 797 and the Board's sterile compounding regulations. COMAR 10.34.37.04 likewise requires a nonresident pharmacy that compounds sterile preparations to follow USP standards and COMAR 10.34.19. [1] [7] [8] [9] [10] [12]

Can you get compounded GLP-1s in Maryland?

Regulatory: Compounded GLP-1 limited

Maryland law lets the required clinical evaluation be asynchronous (Health Occupations 1-1003). An app-based GLP-1 program can meet the prescribing rules only if a Maryland-licensed practitioner verifies the patient's identity, discloses the practitioner's name, contact information, and license type, obtains consent, and does not rely on a static online questionnaire alone (Health Occupations 1-1002; COMAR 10.32.05). The dispensing pharmacy must still hold a Maryland pharmacy or nonresident pharmacy permit. [3] [4] [5] [7] [15]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Maryland?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in Maryland

What you'll actually find in Maryland, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [19] [20] [21]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [22]

What Maryland has done

PeptideAgent has not found a board or legislative action on peptides in Maryland.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [24] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [25] [26] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in Maryland. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. State law says an online questionnaire alone is not enough. [2] [3] [4] [5] [6] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Maryland Board of Pharmacy (Maryland Department of Health); its license search: FDA BeSafeRx: state board of pharmacy license lookups. [23]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [22]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [13] [27] [28]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [23] [29] [30]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [21] [30] [31]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [22] [32] [33] [34] [35] [36]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [22]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [23]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [21]
  • Pharmacy: Is this made for me on a prescription written in my name? [31]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [21] [30]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [21]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in Maryland?

Maryland's Food, Drug, and Cosmetic Act (Health-General Article, Title 21) prohibits selling adulterated or misbranded drugs, and Health Occupations Title 12 limits dispensing of prescription drugs to permitted pharmacies and authorized practitioners. [1] [11] [16]

Peptide-specific notes for Maryland

No peptide-specific rule identified for this jurisdiction. The general compounding and telehealth rules above apply, and the federal record covers semaglutide, tirzepatide, and BPC-157.

Frequently asked questions

Can I get a GLP-1 prescription in Maryland from an online questionnaire or app?

From an app, yes in principle. From a static questionnaire alone, no. Health Occupations sections 1-1002 and 1-1003 let a Maryland-licensed practitioner establish the relationship and perform the required clinical evaluation through an asynchronous telehealth interaction, and the care must meet the in-person standard. The Board of Physicians rule (COMAR 10.32.05.06) bars treating or prescribing based solely on a static online questionnaire. The prescriber still decides whether the information is enough to prescribe safely. [2] [3] [4] [5]

Does a telehealth prescriber need a Maryland license?

Yes. Maryland's telehealth statute applies to practitioners licensed in Maryland, and the Board of Physicians' telehealth regulations in COMAR 10.32.05 require Maryland licensure to treat a patient located in Maryland. [2] [5]

Can an out-of-state pharmacy ship compounded peptides to me in Maryland?

Only if it holds a Maryland nonresident pharmacy permit. Under Health Occupations section 12-403, the pharmacy must submit its latest home-state inspection report and name a Maryland agent for service of process, and a pharmacy that ships compounded sterile preparations such as injectable peptides must also file a USP chapter 797 inspection report from an inspection done within 90 days before its application. Search the Board of Pharmacy license verification before ordering. [1] [7]

Can a Maryland pharmacy compound BPC-157?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Maryland has no state bulks list; peptide eligibility follows the federal 503A framework. [12] [13] [14] [17] [18]

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]Maryland Board of Pharmacy
  2. [2]Maryland Code, Health Occupations section 1-1001, Telehealth definitions
  3. [3]Maryland Code, Health Occupations section 1-1002, Establishing a practitioner-patient relationship through telehealth
  4. [4]Maryland Code, Health Occupations section 1-1003, Telehealth clinical evaluation and prescribing
  5. [5]COMAR 10.32.05, Telehealth (Maryland Board of Physicians), current text as amended effective September 15, 2025 and January 19, 2026
  6. [6]Maryland House Bill 448 (2020), Chapter 15: Health Care Practitioners, Telehealth and Shortage (adds Health Occupations 1-1001 through 1-1006)
  7. [7]Maryland Code, Health Occupations section 12-403, Required standards (including nonresident pharmacies)
  8. [8]COMAR Title 10, Subtitle 34, Board of Pharmacy regulations
  9. [9]COMAR 10.34.37.04, Requirements for nonresident pharmacy operations
  10. [10]Maryland Senate Bill 69 (2015), Chapter 5: repeal of the sterile compounding permit requirement

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Are peptides legal in Maryland?. https://peptideagent.ai/legal/maryland
HTML link
<a href="https://peptideagent.ai/legal/maryland">Are peptides legal in Maryland?</a>, PeptideAgent, updated October 28, 2026.